Tools
GABA Receptor
Introduction
Gamma-aminobutyric acid (GABA) is an amino acid that functions as the primary inhibitory neurotransmitter in the central nervous system (CNS). GABA is synthesized from the excitatory neurotransmitter glutamate and reduces neuronal excitability by causing neuronal hyperpolarization and decreasing neurotransmitter release. The activity of GABA is regulated by binding through 3 receptors—GABA-A, GABA-B, and GABA-C.
GABAergic neurons are located in the hippocampus, thalamus, basal ganglia, hypothalamus, and brainstem. Maintaining a balance between inhibitory neuronal transmission through GABA and excitatory neuronal transmission through glutamate is essential for cell membrane stability and proper neurological function.[1] Disruption of the balance between glutamate and GABA has a functional role in various pathologies, including traumatic brain injury, Alzheimer disease, epilepsy, schizophrenia, and autism.[1][2] The role of GABA receptors in analgesia is also being investigated.[3][4]
Function
Register For Free And Read The Full Article
Search engine and full access to all medical articles- 10 free questions in your specialty
- Free CME/CE Activities
- Free daily question in your email
- Save favorite articles to your dashboard
- Emails offering discounts
Learn more about a Subscription to StatPearls Point-of-Care
Function
Synthesis, Release, and Reuptake
GABA is synthesized from glutamate by the enzyme glutamic acid decarboxylase (GAD), which requires pyridoxal phosphate—a cofactor derived from pyridoxine (vitamin B6). Once formed, GABA is transported into vesicles by the vesicular inhibitory amino acid transporter (VIAAT). These vesicles are released into the postsynaptic terminals of neurons through calcium-dependent exocytosis.[5]
GABA transaminase can be further metabolized by GABA transaminase into succinic semialdehyde (SSA) and succinic acid, which enter the citric acid cycle to participate in energy production.[6] The transamination of GABA into SSA is coupled with the conversion of α-ketoglutarate to glutamate, which is subsequently taken up by the neuron for the synthesis of GABA.
Receptors
GABA receptors are the primary inhibitory receptors in the CNS, and they are classified into 3 types—GABA-A, GABA-B, and GABA-C receptors.[7]
GABA-A receptors: GABA-A receptors are ligand-gated ion channel (ionotropic) heteropentamer receptors composed of a selection of 19 different subunits. These include 6 alpha subunits (α 1-6), 3 beta subunits (β 1-3), 3 gamma subunits (γ 1-3), 3 rho subunits (ρ 1-3), and 1 each of delta (δ), epsilon (ε), pi (π), and theta (θ) subunits. Although numerous combinations are possible with this selection, most GABA-A receptors exist as a combination of 2α and 2β subunits and either a γ- or δ-subunit.[8]
One of the more common combinations is γ2β2α1β2α1 arranged counterclockwise from the center subunit.[9] Different isoforms of the receptor exhibit different physiological and pharmacological properties. Additionally, certain isoforms may have restricted expression based on their function. The binding sites for GABA are located at the β-α interfaces within the receptor.[9][10]
GABA-A receptors are primarily involved in fast synaptic inhibition. When GABA binds to the receptor, an ion channel opens, thereby allowing chloride ions to move across the cell membrane. As chloride is negatively charged, this results in hyperpolarization, making the membrane potential more negative and less sensitive to depolarization. GABA-A receptors are located throughout the CNS, both at postsynaptic and extrasynaptic sites, with high concentrations in the limbic system and the retina.[7]
GABA-B receptors: GABA-B receptors are G-protein–coupled heterodimers composed of B1 (B1a and B1b) and B2 subunits. They function as slow synaptic inhibitors and exert inhibitory effects through the second messenger system. The effect of GABA-B receptor activation depends on whether it occurs at the pre- or postsynaptic terminal. In the presynaptic terminal, GABA binding reduces adenylyl cyclase activity, leading to a decrease in cyclic adenosine monophosphate (cAMP) levels. This action inhibits neurotransmitter release.
Other effects include the inhibition of inward-rectifying calcium channels, further preventing neurotransmitter release. Postsynaptically, the inhibition of adenylyl cyclase decreases protein kinase A signaling and reduces ion channel permeability. Additionally, the stimulation of inward-rectifying potassium channels leads to further hyperpolarization.[11][12]
GABA-C receptors: GABA-C receptors are pentameric ligand-gated ion channels, similar to GABA-A receptors. They are unique in that they consist of only ρ subunits (ρ1, ρ2, and ρ3).[13] The role of GABA-C receptors is not fully understood and remains under investigation, although they appear to have an important role in retinal signal processing.[14][15]
Brain Development
Although GABA functions as an inhibitory neurotransmitter in the adult brain, it acts differently during embryonic development. GABA functions as an excitatory neurotransmitter during the neurodevelopment of the fetus. GABA is believed to be the first neurotransmitter active in the developing brain and has a role in the proliferation of neuronal progenitor cells.[16] High levels of GABA in ventricular areas are associated with increased proliferation and neural progenitor cell size. However, in the subventricular zone, GABA appears to decrease proliferation.[17][18]
Clinical Significance
GABA-A receptors are critical in the modulation of seizures.[19] Chronic exposure to certain xenobiotics that stimulate GABA receptors, such as ethanol and benzodiazepines, can modulate GABA receptor expression and sensitivity. Overstimulation of GABA receptors leads to receptor downregulation and decreased neuronal sensitivity to GABA. When these substances are abruptly discontinued, there is a sudden reduction in the overall inhibitory signal, which can trigger seizures.[20]
In epilepsy, dysfunction or loss of inhibitory interneurons in the cerebral cortex leads to a loss of inhibition of excitatory neurons. This causes neurons to depolarize more easily, resulting in uncontrolled excitation and subsequent seizure activity.[21] Compounds such as picrotoxin and bicuculline, which are GABA antagonists, act as pro-convulsants.[8][22]
Various diseases, including many psychiatric illnesses, have been linked to low levels of GABA. Generalized anxiety is one such example. As an inhibitory neurotransmitter, decreased GABA levels can contribute to feelings of anxiousness. Reduced GABA levels have also been associated with schizophrenia, autism spectrum disorder, and major depressive disorder. Although GABA concentrations may be altered in these psychiatric conditions, treatment with GABA-A receptor agonists is not considered first-line therapy due to their high addiction potential and potentially fatal adverse effects.[2][23]
Inherited Disorders
Inherited disorders of GABA metabolism are rare. The most common conditions include GABA-transaminase deficiency, SSA dehydrogenase (SSADH) deficiency, and homocarnosinosis. Of these, SSADH deficiency is the most prevalent neurotransmitter deficiency. This condition presents clinically with a vague phenotype, a range of neurological manifestations, and psychiatric symptoms. The inability to convert GABA to succinic acid results in the accumulation of gamma-hydroxybutyrate (GHB). Elevated levels of both GABA and GHB can be detected in serum and urine.
Diagnosis can be confirmed through the urinary excretion of GABA and increased signaling in the globus pallidus on magnetic resonance imaging. Key characteristics include expressive language impairment, hypotonia, and seizures. The most common neuropsychiatric issue is sleep disturbance, with other concerns including inattention, hyperactivity, and obsessive-compulsive disorder. Currently, there is no standard treatment for SSADH deficiency.[24]
GABA-transaminase deficiency and homocarnosinosis are much rarer. GABA-transaminase deficiency is an autosomal recessive disorder. Patients may experience seizures that present in the neonatal period, with other manifestations including hypotonia, hyperreflexia, severely delayed psychomotor development, and a high-pitched cry. Elevated concentrations of GABA, homocarnosine, and β-alanine can be found in serum and cerebrospinal fluid.[25]
Homocarnosinosis has been reported in only one family. This disorder results from the accumulation of homocarnosine, a dipeptide composed of GABA and histidine.[26] Key characteristics of this condition include progressive spastic diplegia, intellectual disability, and retinitis pigmentosa.[24]
Poisoning from certain xenobiotics, such as isoniazid, rocket fuel (hydrazine), and the consumption of the false morel (Gyromitra esculenta) mushroom, which contains the hydrazine derivative gyrometrin, can lead to the depletion of GABA.[27][28] Specifically, hydrazine compounds deplete pyridoxine (vitamin B6) and inhibit the formation of pyridoxal phosphate, which in turn inhibits the activity of GAD. This disruption prevents the synthesis of GABA, leading to its eventual depletion and causing seizures that are refractory to benzodiazepines. Treatment involves the administration of pyridoxine.[27]
Other Issues
GABA Agonists
GABA agonists, such as commonly prescribed anticonvulsants, sedatives, and anxiolytics, can increase GABA levels, leading to CNS depression. Prolonged use of these GABA agonists can result in physiological dependence and, in some cases, addiction.[29]
GABA-A receptor agonists: GABA-A receptor agonists include alcohol (ethanol), barbiturates, and benzodiazepines.
- Barbiturates, such as phenobarbital and sodium thiopental, are used less frequently due to their higher risk of respiratory depression compared to benzodiazepines. However, barbiturates, especially phenobarbital, are increasingly utilized in the treatment of acute alcohol withdrawal.[30][31][32][33]
- Benzodiazepines, including lorazepam, diazepam, clonazepam, alprazolam, oxazepam, and chlordiazepoxide, were developed to minimize adverse effects associated with barbiturates, such as respiratory depression. Clinical indications for benzodiazepines include anxiety, agitation, seizures, and muscle spasms. Only short-term use is recommended. Although benzodiazepine overdose can cause significant sedation, respiratory depression rarely occurs when benzodiazepines are taken alone. However, the risk of respiratory depression increases significantly with co-ingestants such as alcohol or opioids. Flumazenil, a benzodiazepine antagonist, is used to reverse overdose in certain situations. However, flumazenil can induce iatrogenic seizures that may be refractory to subsequent benzodiazepine administration, particularly in patients with physiological dependence.[29]
GABA-B receptor agonists: GABA-B receptor agonists include baclofen, sodium oxybate (GHB), and propofol.
- Baclofen is a muscle relaxant commonly used to treat spasticity. This medication is available in oral formulations or can be administered via an implanted pump.
- GHB is approved for the treatment of narcolepsy. GHB is also increasingly used recreationally in the club scene, during "chemsex," and as a drug to facilitate sexual assault.[34][35][36][37] Severe CNS depression is common in individuals who have taken GHB. Significant respiratory depression and obtundation are frequently observed, and it is not uncommon for patients to require intubation.[38]
- Propofol is used for the induction and maintenance of general anesthesia and for sedation in mechanically ventilated patients. Adverse effects include hypotension, apnea, and involuntary body movements.[29][39][40]
GABA analogs: GABA analogs, including valproic acid, pregabalin, gabapentin, and vigabatrin, are used as anticonvulsants, sedatives, and anxiolytics.
- Valproate is prescribed to treat seizures and mood instability. Although it is a GABA analog, the exact mechanism of action of valproate is not fully understood. Valproate is believed to involve multiple mechanisms, including effects on sodium, calcium, and potassium channels, as well as GABAergic actions, such as inhibiting GABA transaminase.[41]
- Pregabalin is used to treat fibromyalgia, diabetic neuropathy, and postherpetic neuralgia. Although it is a GABA analog, it does not act on GABA-mediated neurotransmission. Instead, it primarily inhibits voltage-gated calcium channels, reducing glutamate release.[41][42]
- Gabapentin is approved for the treatment of postherpetic neuralgia and seizures, with off-label uses, including the management of diabetic neuropathy and fibromyalgia.[29] Gabapentin functions similarly to pregabalin by inhibiting voltage-gated calcium channels.[41][42]
GABA Antagonists
GABA antagonists are drugs that inhibit the activation of the GABA receptor, typically by binding to alternative sites on the receptor. Examples include picrotoxin and bicuculline methiodide, which are primarily used for research purposes. GABA antagonists are pro-convulsant and exhibit stimulant properties.[22][43]
Enhancing Healthcare Team Outcomes
GABA is a crucial inhibitory neurotransmitter in the human brain. Dysfunction in the GABA system can lead to various disease processes, resulting in an imbalance between the GABA and glutamate systems. These conditions may include psychiatric illnesses, dementia, drug dependence or addiction, and drug overdose or toxicity. Many of these conditions can be treated with medications, including GABA agonists.
The healthcare team, including physicians, physician assistants, nurse practitioners, nurses, and pharmacists, must possess the knowledge required to safely prescribe and administer these drugs. Each healthcare team member is responsible for monitoring adverse drug effects and periodically reviewing the indications for these medications to minimize risks. Additionally, healthcare providers should be able to recognize signs and symptoms of toxicity, such as severe sedation or respiratory depression, to ensure prompt diagnosis and treatment.
References
Sears SM, Hewett SJ. Influence of glutamate and GABA transport on brain excitatory/inhibitory balance. Experimental biology and medicine (Maywood, N.J.). 2021 May:246(9):1069-1083. doi: 10.1177/1535370221989263. Epub 2021 Feb 7 [PubMed PMID: 33554649]
Wong CG, Bottiglieri T, Snead OC 3rd. GABA, gamma-hydroxybutyric acid, and neurological disease. Annals of neurology. 2003:54 Suppl 6():S3-12 [PubMed PMID: 12891648]
Level 3 (low-level) evidenceQian X, Zhao X, Yu L, Yin Y, Zhang XD, Wang L, Li JX, Zhu Q, Luo JL. Current status of GABA receptor subtypes in analgesia. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie. 2023 Dec:168():115800. doi: 10.1016/j.biopha.2023.115800. Epub 2023 Nov 6 [PubMed PMID: 37935070]
Level 2 (mid-level) evidenceBenke D. GABA(B) Receptors and Pain. Current topics in behavioral neurosciences. 2022:52():213-239. doi: 10.1007/7854_2020_130. Epub [PubMed PMID: 32812203]
Malcangio M, Bowery NG. GABA and its receptors in the spinal cord. Trends in pharmacological sciences. 1996 Dec:17(12):457-62 [PubMed PMID: 9014500]
Cavalcanti-de-Albuquerque JP, de-Souza-Ferreira E, de Carvalho DP, Galina A. Coupling of GABA Metabolism to Mitochondrial Glucose Phosphorylation. Neurochemical research. 2022 Feb:47(2):470-480. doi: 10.1007/s11064-021-03463-2. Epub 2021 Oct 8 [PubMed PMID: 34623563]
Sigel E, Steinmann ME. Structure, function, and modulation of GABA(A) receptors. The Journal of biological chemistry. 2012 Nov 23:287(48):40224-31. doi: 10.1074/jbc.R112.386664. Epub 2012 Oct 4 [PubMed PMID: 23038269]
Level 3 (low-level) evidenceKim JJ, Hibbs RE. Direct Structural Insights into GABA(A) Receptor Pharmacology. Trends in biochemical sciences. 2021 Jun:46(6):502-517. doi: 10.1016/j.tibs.2021.01.011. Epub 2021 Mar 3 [PubMed PMID: 33674151]
Ghit A, Assal D, Al-Shami AS, Hussein DEE. GABA(A) receptors: structure, function, pharmacology, and related disorders. Journal, genetic engineering & biotechnology. 2021 Aug 21:19(1):123. doi: 10.1186/s43141-021-00224-0. Epub 2021 Aug 21 [PubMed PMID: 34417930]
Goldschen-Ohm MP. Benzodiazepine Modulation of GABA(A) Receptors: A Mechanistic Perspective. Biomolecules. 2022 Nov 30:12(12):. doi: 10.3390/biom12121784. Epub 2022 Nov 30 [PubMed PMID: 36551212]
Level 3 (low-level) evidencePadgett CL, Slesinger PA. GABAB receptor coupling to G-proteins and ion channels. Advances in pharmacology (San Diego, Calif.). 2010:58():123-47. doi: 10.1016/S1054-3589(10)58006-2. Epub [PubMed PMID: 20655481]
Level 3 (low-level) evidenceEvenseth LSM, Gabrielsen M, Sylte I. The GABA(B) Receptor-Structure, Ligand Binding and Drug Development. Molecules (Basel, Switzerland). 2020 Jul 7:25(13):. doi: 10.3390/molecules25133093. Epub 2020 Jul 7 [PubMed PMID: 32646032]
Enz R. GABA(C) receptors: a molecular view. Biological chemistry. 2001 Aug:382(8):1111-22 [PubMed PMID: 11592392]
Lorenz-Guertin JM, Povysheva N, Chapman CA, MacDonald ML, Fazzari M, Nigam A, Nuwer JL, Das S, Brady ML, Vajn K, Bambino MJ, Weintraub ST, Johnson JW, Jacob TC. Inhibitory and excitatory synaptic neuroadaptations in the diazepam tolerant brain. Neurobiology of disease. 2023 Sep:185():106248. doi: 10.1016/j.nbd.2023.106248. Epub 2023 Aug 1 [PubMed PMID: 37536384]
Zhang D, Pan ZH, Awobuluyi M, Lipton SA. Structure and function of GABA(C) receptors: a comparison of native versus recombinant receptors. Trends in pharmacological sciences. 2001 Mar:22(3):121-32 [PubMed PMID: 11239575]
Furukawa T, Fukuda A. Maternal taurine as a modulator of Cl(-) homeostasis as well as of glycine/GABA(A) receptors for neocortical development. Frontiers in cellular neuroscience. 2023:17():1221441. doi: 10.3389/fncel.2023.1221441. Epub 2023 Aug 3 [PubMed PMID: 37601283]
Wang DD, Kriegstein AR. Defining the role of GABA in cortical development. The Journal of physiology. 2009 May 1:587(Pt 9):1873-9. doi: 10.1113/jphysiol.2008.167635. Epub 2009 Jan 19 [PubMed PMID: 19153158]
Wu C, Sun D. GABA receptors in brain development, function, and injury. Metabolic brain disease. 2015 Apr:30(2):367-79. doi: 10.1007/s11011-014-9560-1. Epub 2014 May 13 [PubMed PMID: 24820774]
Level 3 (low-level) evidencePerucca E, Bialer M, White HS. New GABA-Targeting Therapies for the Treatment of Seizures and Epilepsy: I. Role of GABA as a Modulator of Seizure Activity and Recently Approved Medications Acting on the GABA System. CNS drugs. 2023 Sep:37(9):755-779. doi: 10.1007/s40263-023-01027-2. Epub 2023 Aug 21 [PubMed PMID: 37603262]
Umar Z, Haseeb Ul Rasool M, Muhammad S, Yousaf S, Nassar M, Ilyas U, Hosna AU, Parikh A, Bhangal R, Ahmed N, Ariyaratnam J, Trandafirescu T. Phenobarbital and Alcohol Withdrawal Syndrome: A Systematic Review and Meta-Analysis. Cureus. 2023 Jan:15(1):e33695. doi: 10.7759/cureus.33695. Epub 2023 Jan 12 [PubMed PMID: 36788902]
Level 1 (high-level) evidenceLiu YQ, Yu F, Liu WH, He XH, Peng BW. Dysfunction of hippocampal interneurons in epilepsy. Neuroscience bulletin. 2014 Dec:30(6):985-998. doi: 10.1007/s12264-014-1478-4. Epub 2014 Nov 5 [PubMed PMID: 25370443]
Treiman DM. GABAergic mechanisms in epilepsy. Epilepsia. 2001:42 Suppl 3():8-12 [PubMed PMID: 11520315]
Level 3 (low-level) evidenceSchür RR, Draisma LW, Wijnen JP, Boks MP, Koevoets MG, Joëls M, Klomp DW, Kahn RS, Vinkers CH. Brain GABA levels across psychiatric disorders: A systematic literature review and meta-analysis of (1) H-MRS studies. Human brain mapping. 2016 Sep:37(9):3337-52. doi: 10.1002/hbm.23244. Epub 2016 May 4 [PubMed PMID: 27145016]
Level 1 (high-level) evidencePearl PL, Hartka TR, Cabalza JL, Taylor J, Gibson MK. Inherited disorders of GABA metabolism. Future neurology. 2006 Sep:1(5):631-636 [PubMed PMID: 23842532]
Oshi A, Alfaifi A, Seidahmed MZ, Al Hussein K, Miqdad A, Samadi A, Abdelbasit O. GABA transaminase deficiency. Case report and literature review. Clinical case reports. 2021 Mar:9(3):1295-1298. doi: 10.1002/ccr3.3753. Epub 2021 Jan 9 [PubMed PMID: 33768830]
Level 3 (low-level) evidenceSjaastad O, Berstad J, Gjesdahl P, Gjessing L. Homocarnosinosis. 2. A familial metabolic disorder associated with spastic paraplegia, progressive mental deficiency, and retinal pigmentation. Acta neurologica Scandinavica. 1976 Apr:53(4):275-90 [PubMed PMID: 1266573]
Nguyen HN, Chenoweth JA, Bebarta VS, Albertson TE, Nowadly CD. The Toxicity, Pathophysiology, and Treatment of Acute Hydrazine Propellant Exposure: A Systematic Review. Military medicine. 2021 Feb 26:186(3-4):e319-e326. doi: 10.1093/milmed/usaa429. Epub [PubMed PMID: 33175959]
Level 1 (high-level) evidenceVohra V, Dirks A, Bonito G, James T, Carroll DK. A 19-year longitudinal assessment of gyromitrin-containing (Gyromitra spp.) mushroom poisonings in Michigan. Toxicon : official journal of the International Society on Toxinology. 2024 Aug 28:247():107825. doi: 10.1016/j.toxicon.2024.107825. Epub 2024 Jun 20 [PubMed PMID: 38908526]
Chen X, de Haas S, de Kam M, van Gerven J. An Overview of the CNS-Pharmacodynamic Profiles of Nonselective and Selective GABA Agonists. Advances in pharmacological sciences. 2012:2012():134523. doi: 10.1155/2012/134523. Epub 2012 Jan 29 [PubMed PMID: 22363345]
Level 3 (low-level) evidenceRosenson J, Clements C, Simon B, Vieaux J, Graffman S, Vahidnia F, Cisse B, Lam J, Alter H. Phenobarbital for acute alcohol withdrawal: a prospective randomized double-blind placebo-controlled study. The Journal of emergency medicine. 2013 Mar:44(3):592-598.e2. doi: 10.1016/j.jemermed.2012.07.056. Epub 2012 Sep 19 [PubMed PMID: 22999778]
Level 1 (high-level) evidenceMalone D, Costin BN, MacElroy D, Al-Hegelan M, Thompson J, Bronshteyn Y. Phenobarbital versus benzodiazepines in alcohol withdrawal syndrome. Neuropsychopharmacology reports. 2023 Dec:43(4):532-541. doi: 10.1002/npr2.12347. Epub 2023 Jun 27 [PubMed PMID: 37368937]
Tidwell WP, Thomas TL, Pouliot JD, Canonico AE, Webber AJ. Treatment of Alcohol Withdrawal Syndrome: Phenobarbital vs CIWA-Ar Protocol. American journal of critical care : an official publication, American Association of Critical-Care Nurses. 2018 Nov:27(6):454-460. doi: 10.4037/ajcc2018745. Epub [PubMed PMID: 30385536]
Shah P, Stegner-Smith KL, Rachid M, Hanif T, Dodd KW. Front-Loaded Versus Low-Intermittent Phenobarbital Dosing for Benzodiazepine-Resistant Severe Alcohol Withdrawal Syndrome. Journal of medical toxicology : official journal of the American College of Medical Toxicology. 2022 Jul:18(3):198-204. doi: 10.1007/s13181-022-00900-8. Epub 2022 Jun 6 [PubMed PMID: 35668289]
Di Trana A, Beck R, Del Rio A. Management of GHB acute intoxications. La Clinica terapeutica. 2021 Jan-Feb:171(1):e49-e51. doi: 10.7417/CT.2021.2280. Epub [PubMed PMID: 33346326]
Drevin G, Rossi LH, Férec S, Briet M, Abbara C. Chemsex/slamsex-related intoxications: A case report involving gamma-hydroxybutyrate (GHB) and 3-methylmethcathinone (3-MMC) and a review of the literature. Forensic science international. 2021 Apr:321():110743. doi: 10.1016/j.forsciint.2021.110743. Epub 2021 Feb 20 [PubMed PMID: 33640780]
Level 3 (low-level) evidenceLee H, Labhardt D, Willmott D. GHB, Chemsex and Chemical Submission: Investigating the Role of Sexuality on Victim Empathy and Blame Attribution in Drug-Facilitated Sexual Assault against Men. Behavioral sciences (Basel, Switzerland). 2024 Oct 8:14(10):. doi: 10.3390/bs14100913. Epub 2024 Oct 8 [PubMed PMID: 39457785]
Kim GJ, Park SJ, Kim L, Kim KH, Kim S, An JE, Shin CJ, Seo SE, Jo S, Kim J, Ha S, Seo HW, Rho MC, Kwon DH, Kim WK, Jeong G, Ryu JC, Kim JJ, Kwon OS. Second Skin as Self-Protection Against γ-Hydroxybutyrate. ACS nano. 2023 Dec 26:17(24):25405-25418. doi: 10.1021/acsnano.3c08840. Epub 2023 Dec 7 [PubMed PMID: 38060256]
Berling I, Isoardi K, Harris K, Downes MA, Lovett C, Isbister GK. Growing burden of gamma-hydroxybutyrate intoxication on emergency department resource utilisation. Emergency medicine Australasia : EMA. 2024 Oct:36(5):792-794. doi: 10.1111/1742-6723.14467. Epub 2024 Jul 19 [PubMed PMID: 39030972]
Cash CD. Gamma-hydroxybutyrate: an overview of the pros and cons for it being a neurotransmitter and/or a useful therapeutic agent. Neuroscience and biobehavioral reviews. 1994 Summer:18(2):291-304 [PubMed PMID: 7914688]
Level 3 (low-level) evidenceBrohan J, Goudra BG. The Role of GABA Receptor Agonists in Anesthesia and Sedation. CNS drugs. 2017 Oct:31(10):845-856. doi: 10.1007/s40263-017-0463-7. Epub [PubMed PMID: 29039138]
Hakami T. Neuropharmacology of Antiseizure Drugs. Neuropsychopharmacology reports. 2021 Sep:41(3):336-351. doi: 10.1002/npr2.12196. Epub 2021 Jul 23 [PubMed PMID: 34296824]
Sills GJ, Rogawski MA. Mechanisms of action of currently used antiseizure drugs. Neuropharmacology. 2020 May 15:168():107966. doi: 10.1016/j.neuropharm.2020.107966. Epub 2020 Jan 14 [PubMed PMID: 32120063]
Johnston GA. Advantages of an antagonist: bicuculline and other GABA antagonists. British journal of pharmacology. 2013 May:169(2):328-36. doi: 10.1111/bph.12127. Epub [PubMed PMID: 23425285]
Level 3 (low-level) evidence